İçeriğe geç
akaturk Akademik ölçüm
Giriş yap Kayıt ol

OpenAlex konusu

Myasthenia Gravis and Thymoma

Bu sayfa OpenAlex konu etiketine göre çalışmaları ve o konuda görünen akademisyenleri listeler. YÖKSİS temel alan / yan dal değildir.

OpenAlex 2.483 eser 36 yazar konusu

Çalışmalar

2.483 eser

  1. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  2. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  3. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  4. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  5. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.9%

    Özet henüz yok.

  6. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors 2014
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.7%

    Özet henüz yok.

  7. Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database 2012
    OpenAlex üst %1 OpenAlex 99.6%

    Özet henüz yok.

  8. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes 2013
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.3%

    Özet henüz yok.

  9. A comprehensive analysis of the epidemiology and clinical characteristics of anti LRP4 in myasthenia gravis 2014
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 99.1%

    Özet henüz yok.

  10. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts 2011
    YÖKSİS SJR Q2 OpenAlex üst %10 OpenAlex 93.9%

    BACKGROUND: Histopathological grading of ependymoma has been controversial with respect to its reproducibility and clinical significance. In a 3-phase study, we reviewed the pathology of 229 intracranial ependymomas from European trial cohorts of infants (2 trials - SFOP/CNS9204) and older children (2 trials - AIEOP/C…

  11. Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis 2019
    YÖKSİS SJR Q2 JCR Q3 OpenAlex üst %1 OpenAlex 99.6%

    INTRODUCTION: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. METHODS:…

  12. Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis 2019
    YÖKSİS SJR Q2 JCR Q3 OpenAlex üst %1 OpenAlex 99.6%

    INTRODUCTION: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. METHODS:…

Akademisyenler

36 akademisyen